SLS-004

N/A

Report date: 2025/09/01 16:35:30

Base Information

Drug NameSLS-004

Drug Alias NameSLS-004

ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Stem cell therapy > Induced pluripotent stem cells therapy

Mechanisms of ActionGene expression modulatorsSynuclein alpha inhibitors

TargetsSynuclein alpha

Therapy Area/IndicationsParkinson Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesDuke University

China Registration ClassN/A

Develop Information

Active CompaniesDuke University

Inactive CompaniesN/A

Active IndicationsParkinson Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A